Multiple mechanisms of ligand interaction with the human organic cation transporter, OCT2

American Journal of Physiology - Renal Physiology

Volumn 304, Issue 1, 2013, Pages

  Harper, Jaclyn N ^a   Wright, Stephen H ^a  

^a UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

Author keywords

Multidrug; Organic cation; Proximal tubule; Transport

Indexed keywords

1 METHYL 4 PHENYLPYRIDINIUM; ADRENOSTERONE; CARVEDILOL; CIMETIDINE; CORTICOSTERONE; DIFENIDOL; IMIPRAMINE; METFORMIN; ORGANIC CATION TRANSPORTER 2; ORGANIC CATION TRANSPORTER 2 INHIBITOR; PHENYLTOLOXAMINE; PROTEIN INHIBITOR; PYRIMETHAMINE; TACRINE; TETRYLAMMONIUM; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; FEMALE; HAMSTER; IC 50; LIQUID CHROMATOGRAPHY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TANDEM MASS SPECTROMETRY;

EID: 84871904912     PISSN: 1931857X     EISSN: 15221466     Source Type: Journal    
DOI: 10.1152/ajprenal.00486.2012     Document Type: Article

References (56)

1. Ahlin G, Karlsson J, Pedersen JM, Gustavsson L, Larsson R, Matsson P, Norinder U, Bergstrom CA, Artursson P. Structural requirements for drug inhibition of the liver specific human organic cation transport protein. J Med Chem 51: 5932-5942, 2008.
2. Amphoux A, Vialou V, Drescher E, Bruss M, La Cour CM, Rochat C, Millan MJ, Giros B, Bonisch H, Gautron S. Differential pharmacological in vitro properties of organic cation transporters and regional distribution in rat brain. Neuropharmacology 50: 941-952, 2006.
3. Arndt P, Volk C, Gorboulev V, Budiman T, Popp C, Ulzheimer-Teuber I, Akhoundova A, Koppatz S, Bamberg E, Nagel G, Koepsell H. Interaction of cations, anions, and weak base quinine with rat renal cation transporter rOCT2 compared with rOCT1. Am J Physiol Renal Physiol 281: F454-F468, 2001.
4. Astorga B, Ekins S, Morales M, Wright SH. Molecular determinants of ligand selectivity for the human multidrug and toxin extrusion proteins, MATE1 and MATE-2K. J Pharmacol Exp Ther 341: 743-755, 2012.
5. Barendt WM, Wright SH. The human organic cation transporter (hOCT2) recognizes the degree of substrate ionization. J Biol Chem 277: 22491-22496, 2002.
6. Bednarczyk D, Ekins S, Wikel JH, Wright SH. Influence of molecular structure on substrate binding to the human organic cation transporter, hOCT1. Mol Pharm 63: 489-498, 2003.
7. Bednarczyk D, Mash EA, Aavula BR, Wright SH. NBD-TMA: a novel fluorescent substrate of the peritubular organic cation transporter of renal proximal tubules. Pflügers Arch 440: 184-192, 2000.
8. Brooker L, Parr MK, Cawley A, Flenker U, Howe C, Kazlauskas R, Schanzer W, George A. Development of criteria for the detection of adrenosterone administration by gas chromatography-mass spectrometry and gas chromatography-combustion-isotope ratio mass spectrometry for doping control. Drug Test Anal 1: 587-595, 2009.
9. Budiman T, Bamberg E, Koepsell H, Nagel G. Mechanism of electrogenic cation transport by the cloned organic cation transporter 2 from rat. J Biol Chem 275: 29413-29420, 2000.
10. Busch AE, Quester S, Ulzheimer JC, Waldegger S, Gorboulev V, Arndt P, Lang F, Koepsell H. Electrogenic properties and substrate specificity of the polyspecific rat cation transporter rOCT1. J Biol Chem 271: 32599-32604, 1996.
11. Dresser MJ, Gray AT, Giacomini KM. Kinetic and selectivity differences between rodent, rabbit, and human organic cation transporters (OCT1). J Pharmacol Exp Ther 292: 1146-1152, 2000.
12. Dresser MJ, Xiao G, Leabman MK, Gray AT, Giacomini KM. Interactions of n-tetraalkylammonium compounds and biguanides with a human renal organic cation transporter (hOCT2). Pharm Res 19: 1244-1247, 2002.
13. Garrigues A, Loiseau N, Delaforge M, Ferte J, Garrigos M, Andre F, Orlowski S. Characterization of two pharmacophores on the multidrug transporter P-glycoprotein. Mol Pharmacol 62: 1288-1298, 2002.
14. Giacomini KM, Huang SM, Tweedie DJ, Benet LZ, Brouwer KL, Chu X, Dahlin A, Evers R, Fischer V, Hillgren KM, Hoffmaster KA, Ishikawa T, Keppler D, Kim RB, Lee CA, Niemi M, Polli JW, Sugiyama Y, Swaan PW, Ware JA, Wright SH, Wah YS, Zamek-Gliszczynski MJ, Zhang L. Membrane transporters in drug development. Nat Rev Drug Discov 9: 215-236, 2010.
15. Gorboulev V, Shatskaya N, Volk C, Koepsell H. Subtype-specific affinity for corticosterone of rat organic cation transporters rOCT1 and rOCT2 depends on three amino acids within the substrate binding region. Mol Pharmacol 67: 1612-1619, 2005.
16. Gorboulev V, Ulzheimer JC, Akhoundova A, Ulzheimer-Teuber I, Karbach U, Quester S, Baumann C, Lang F, Busch AE, Koepsell H. Cloning and characterization of two human polyspecific organic cation transporters. DNA Cell Biol 16: 871-881, 1997.
17. Gorboulev V, Volk C, Arndt P, Akhoundova A, Koepsell H. Selectivity of the polyspecific cation transporter rOCT1 is changed by mutation of aspartate 475 to glutamate. Mol Pharmacol 56: 1254-1261, 1999.
18. Gorbunov D, Gorboulev V, Shatskaya N, Mueller T, Bamberg E, Friedrich T, Koepsell H. High-affinity cation binding to transporter OCT1 induces movement of helix 11 and blocks transport after mutations in a modelled interaction domain between two helices. Mol Pharmacol 73: 50-61, 2008.
19. Gründemann D, Gorboulev V, Gambaryan S, Veyhl M, Koepsell H. Drug excretion mediated by a new prototype of polyspecific transporter. Nature 372: 549-552, 1994.
20. Hayer-Zillgen M, Bruss M, Bonisch H. Expression and pharmacological profile of the human organic cation transporters hOCT1, hOCT2 and hOCT3. Br J Pharmacol 136: 829-836, 2002.
21. Ito S, Kusuhara H, Yokochi M, Toyoshima J, Inoue K, Yuasa H, Sugiyama Y. Competitive inhibition of the luminal efflux by MATEs, but not basolateral uptake by OCT2, is the likely mechanism underlying the pharmacokinetic drug-drug interactions caused by cimetidine in the kidney. J Pharmacol Exp Ther 340: 393-403, 2012.
22. Jung N, Lehmann C, Rubbert A, Knispel M, Hartmann P, van Lunzen J, Stellbrink HJ, Faetkenheuer G, Taubert D. Relevance of the organic cation transporters 1 and 2 for antiretroviral therapy in human immunodeficiency virus infection. Drug Metab Dispos 36: 1616-1623, 2008.
23. Kekuda R, Prasad PD, Wu X, Wang H, Fei YJ, Leibach FH, Ganapathy V. Cloning and functional characterization of a potential-sensitive, polyspecific organic cation transporter (OCT3) most abundantly expressed in placenta. J Biol Chem 273: 15971-15979, 1998.
24. Kido Y, Matsson P, Giacomini KM. Profiling of a prescription drug library for potential renal drug-drug interactions mediated by the organic cation transporter 2. J Med Chem 54: 4548-4558, 2011.
25. Kimura N, Masuda S, Tanihara Y, Ueo H, Okuda M, Katsura T, Inui K. Metformin is a superior substrate for renal organic cation transporter OCT2 rather than hepatic OCT1. Drug Metab Pharmacokinet 20: 379-386, 2005.
26. Koepsell H. Substrate recognition and translocation by polyspecific organic cation transporters. Biol Chem 392: 95-101, 2011.
27. Kusuhara H, Ito S, Kumagai Y, Jiang M, Shiroshita T, Moriyama Y, Inoue K, Yuasa H, Sugiyama Y. Effects of a MATE protein inhibitor, pyrimethamine, on the renal elimination of metformin at oral microdose and at therapeutic dose in healthy subjects. Clin Pharmacol Ther 89: 837-844, 2011.
28. Lacko L, Burger M. Common carrier system for sugar transport in human red cells. Nature 191: 881-882, 1961.
29. Lee WK, Reichold M, Edemir B, Ciarimboli G, Warth R, Koepsell H, Thevenod F. Organic cation transporters OCT1, 2, and 3 mediate high-affinity transport of the mutagenic vital dye ethidium in the kidney proximal tubule. Am J Physiol Renal Physiol 296: F1504-F1513, 2009.
30. Lepist EI, Ray AS. Renal drug-drug interactions: what we have learned and where we are going. Expert Opin Drug Metab Toxicol 8: 433-448, 2012.
31. Malo C, Berteloot A. Analysis of kinetic data in transport studies: new insights from kinetic studies of Na-D-glucose cotransport in human intestinal brush-border membrane vesicles using a fast sampling, rapid filtration apparatus. J Membr Biol 122: 127-141, 1991.
32. Marcelin-Jimenez G, Morales-Martinez M, Angeles-Moreno AP, Mendoza-Morales L. Ultra-fast chromatographic micro-assay for quantification of diphenidol in plasma: application in an oral multi-dose switchability trial. Biomed Chromatogr 22: 1143-1148, 2008.
33. Ming X, Ju W, Wu H, Tidwell RR, Hall JE, Thakker DR. Transport of dicationic drugs pentamidine and furamidine by human organic cation transporters. Drug Metab Dispos 37: 424-430, 2009.
34. Minuesa G, Volk C, Molina-Arcas M, Gorboulev V, Erkizia I, Arndt P, Clotet B, Pastor-Anglada M, Koepsell H, Martinez-Picado J. Transport of lamivudine [()-beta-L-2=,3=-dideoxy-3=-thiacytidine] and high affinity interaction of nucleoside reverse transcriptase inhibitors with human organic cation transporters 1, 2, and 3. J Pharmacol Exp Ther 329: 252-261, 2009.
35. Moaddel R, Ravichandran S, Bighi F, Yamaguchi R, Wainer IW. Pharmacophore modelling of stereoselective binding to the human organic cation transporter (hOCT1). Br J Pharmacol 151: 1305-1314, 2007.
36. Motohashih Sakurai Y, Saito H, Masuda S, Urakami Y, Goto M, Fukatsu A, Ogawa O, Inui K. Gene expression levels and immunolocalization of organic ion transporters in the human kidney. J Am Soc Nephrol 13: 866-874, 2002.
37. Muller J, Lips KS, Metzner L, Neubert RH, Koepsell H, Brandsch M. Drug specificity and intestinal membrane localization of human organic cation transporters (OCT). Biochem Pharmacol 70: 1851-1860, 2005.
38. Nassar AE, Talaat RE, Tokuno H. Drug interactions: concerns and current approaches. IDrugs 10: 47-52, 2007.
39. Nies AT, Koepsell H, Damme K, Schwab M. Organic cation transporters (OCTs, MATEs), in vitro and in vivo evidence for the importance in drug therapy. Handb Exp Pharmacol 201: 105-167, 2011.
40. Okuda M, Saito H, Urakami Y, Takano M, Inui KI. cDNA cloning and functional expression of a novel rat kidney organic cation transporter, OCT2. Biochem Biophys Res Commun 224: 500-507, 1996.
41. Pascaud C, Garrigos M, Orlowski S. Multidrug resistance transporter P-glycoprotein has distinct but interacting binding sites for cytotoxic drugs and reversing agents. Biochem J 333: 351-358, 1998.
42. Pelis RM, Dangprapai Y, Wunz TM, Wright SH. Inorganic mercury interacts with cysteine residues (C451 and C474) of hOCT2 to reduce its transport activity. Am J Physiol Renal Physiol 292: F1583-F1591, 2007.
43. Pelis RM, Wright SH. Renal transport of organic anions and cations. Compr Physiol 1: 1795-1835, 2011.
44. Rosenberg T, Wilbrandt W. Uphill transport induced by counterflow. J Gen Physiol 41: 289-296, 1957.
45. Ross CR, Holohan PD. Transport of organic anions and cations in isolated renal plasma membranes. Annu Rev Pharmacol Toxicol 23: 65-85, 1983.
46. Schomig E, Lazar A, Grundemann D. Extraneuronal monoamine transporter and organic cation transporters 1 and 2: a review of transport efficiency. Handb Exp Pharmacol 175: 151-180, 2006.
47. Segel IH. Enzyme Kinetics. New York: Wiley, 1975, p. 161-192.
48. Stein WD. The Movement of Molecules Across Cell Membranes. New York: Academic, 1967, p. 143-148.
49. Suhre WM, Ekins S, Chang C, Swaan PW, Wright SH. Molecular determinants of substrate/inhibitor binding to the human and rabbit renal organic cation transporters, hOCT2 and rbOCT2. Mol Pharmacol 67: 1067-1077, 2005.
50. Tahara H, Kusuhara H, Endou H, Koepsell H, Imaoka T, Fuse E, Sugiyama Y. A species difference in the transport activities of h2 receptor antagonists by rat and human renal organic anion and cation transporters. J Pharmacol Exp Ther 315: 337-345, 2005.
51. Varma MV, Feng B, Obach RS, Troutman MD, Chupka J, Miller HR, El-Kattan A. Physicochemical determinants of human renal clearance. J Med Chem 52: 4844-4852, 2009.
52. Volk C, Gorboulev V, Budiman T, Nagel G, Koepsell H. Different affinities of inhibitors to the outwardly and inwardly directed substrate binding site of organic cation transporter 2. Mol Pharmacol 64: 1037-1047, 2003.
53. Wright SH, Wunz TM, Wunz TP. Structure and interaction of inhibitors with the TEA/H exchanger of rabbit renal brush border membranes. Pflügers Arch 429: 313-324, 1995.
54. Zhang X, Shirahatti NV, Mahadevan D, Wright SH. A conserved glutamate residue in transmembrane helix 10 influences substrate specificity of rabbit OCT2 (SLC22A2). J Biol Chem 280: 34813-34822, 2005.
55. Zolk O, Solbach TF, Konig J, Fromm MF. Functional characterization of the human organic cation transporter 2 variant p.270Ala Ser. Drug Metab Dispos 37: 1312-1318, 009.
56. Zolk O, Solbach TF, Konig J, Fromm MF. Structural determinants of inhibitor interaction with the human organic cation transporter OCT2 (SLC22A2). Naunyn Schmiedebergs Arch Pharmacol 379: 337-348, 2009.